NEW! Anti-SARS-CoV-2 Rapid Test now available

Mobidiag is now offering a rapid and easy to use immunoassay to detect coronavirus (COVID-19) infection.

The Anti-SARS-CoV-2 Rapid Test uses the lateral flow technology and allows detection of IgG and IgM from human serum, whole blood or plasma in about 15 minutes.

Developed by Autobio Diagnostics, key partner of Mobidiag and leading clinical diagnostics company in the Chinese the market, the Anti-SARS-CoV-2 test is now available through Mobidiag sales channels as well as our local distributors (except in Portugal, the Netherlands and Ukraine).

Continue Reading

Development of Novodiag® assay for safe and easy molecular testing of novel coronavirus and influenza viruses

Novodiag® assay rapidly detects coronavirus and influenzas;
provides safety for users with a closed system;
easy to use with no need for highly trained personnel in high risk and hard to reach areas

Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.

The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.

Continue Reading

Mobidiag Secures Additional Funding from Business Finland for Rapid Sepsis Diagnostic Test

ESPOO, Finland, January 07, 2020 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has been granted EUR 1.5 million ($1.65 million) additional funding from Business Finland (formerly Tekes) for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform. This additional funding has been secured as a result of strong progress in the development of the assay and the completion of key milestones by Mobidiag since the award of the first grant in May 2018. The new funding brings the total loan to EUR 3 million ($3.3 million).

Continue Reading

Mobidiag Symposium on Innovative Molecular Diagnostics to be held for Third year at RICAI Annual Meeting

PARIS, France, December 11th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, will host a symposium at the 39th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI) conference in Paris, from the 16th to 17th of December.

The RICAI conference is an annual meeting bringing together leading French clinicians and microbiologists (parasitologists, virologists, bacteriologists) and innovative commercial companies in diagnostics.

Continue Reading

Mobidiag Appoints Joseph Bernardo as Senior Strategic Advisor

ESPOO, Finland, December 10, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the appointment of Joseph E. Bernardo as Senior Strategic Advisor to the Company.

Mr. Bernardo has over twenty years of experience in the diagnostics industry including a significant tenure as a President at Thermo Fisher Scientific, working across a number of divisions including Clinical Next-Generation Sequencing and Oncology, Immuno-Diagnostics, Anatomic Pathology and Fisher HealthCare, the hospital laboratory distribution business of Thermo Fisher.

Continue Reading

Mobidiag signs new international agreements for distribution of its Amplidiag® and Novodiag® diagnostic solutions

Agreements signed in Poland, Ukraine, Romania and Israel, with more in discussions.

ESPOO, Finland, October 29th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.

Continue Reading

NEW! Novodiag® Stool Parasites, comprehensive and cost-effective molecular diagnostic test for detection of intestinal parasites

CE-IVD marking of Novodiag® Stool Parasites, the 4th molecular test on the automated system Novodiag®, for detection of the most common protozoan, helminths and microsporidia in one single test.

ESPOO, Finland, October 09, 2019 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.

Continue Reading

Combatting Antimicrobial Resistance – Molecular Diagnostics Holds the Key

Antibiotic resistant bacteria are one of the major threats to the global healthcare system. Some have commented that it is a more immediate threat to us than global warming. A UK independent review estimated that unless effective action is taken, drug-resistant strains of certain bacterial infections will claim 10 million lives each year by 2050. This would be a horrific and tragic loss of life. This unchecked spread of infectious disease was also predicted to result in an economic cost of 100 trillion USD over the next 35 years (1).

Continue Reading

Novodiag® CarbaR+ featured in Biomedical Scientist magazine – Complete evaluation by Nottingham University Hospital QMC

The article features the successful evaluation of Novodiag® CarbaR+ conducted by Nottingham University Hospitals, NHS Trust, Clinical Microbiology, Queen’s Medical Centre.

Shova Sharma, Associate Practitioner & Experimental Lead of the evaluation and Su Sewaa, Deputy Service Manager of NUH QMC have recently evaluated the test and their results are featured in this month´s Biomedical Scientist issue. NUH Clinical Microbiology will be publishing poster of the evaluation in October 2019 at EMMD in the Netherlands.

Continue Reading

Mobidiag´s Novodiag® CarbaR+ test is one of the finalists at the International Medtech Insight Award 2019

Delighted to announce that Mobidiag´s Novodiag® CarbaR+ test has been shortlisted for Best Technological Innovation: Diagnostics at the 2019 Medtech Insight Awards.

“This Award will recognize the efforts of an individual, team, or company that developed an innovative medical device or diagnostic that makes significant contributions to advancing patient treatment. The judges will be looking for the product that represents the most innovative new approach to care by addressing an unmet clinical need; by changing the practice of health care to be more effective, efficient or less error-prone; or by expanding technology to new patient populations.”

Continue Reading